Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic Grade 3 Neuroendocrine Neoplasms: A Retrospective International Multicenter Study

#2072

Introduction: Gastroenteropancreatic (GEP) grade 3 neuroendocrine neoplasms (NEN G3) are rare, highly malignant neoplasms with poor prognosis and limited therapeutic options. Median survival following chemotherapy is only 10-12 months.

Aim(s): Our aim was to assess the outcome after peptide receptor radionuclide therapy (PRRT) in patients with GEP NEN G3.

Materials and methods: In a retrospective international multicenter study we analyzed the outcome of PRRT in patients with GEP NEN G3, defined as Ki67>20%. Using Kaplan-Meier estimation, Progression Free Survival (PFS) and overall survival (OS) were calculated.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Skovgaard D

Authors: Skovgaard D, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H,

Keywords: neuroendocrine neoplasms, WHO grade 3, PRRT, Progression-free survival, Overall survival,